Pharmacology: Dabigatran specific antidote

A specific antidote for dabigatran: functional and structural characterization.

Dabigatran etexilate is a direct thrombin inhibitor and used widely as an anticoagulant for the prevention of stroke in patients with atrial fibrillation. However, anticoagulation therapy can be associated with an increased risk of bleeding. Here, we present data on the identification, humanization, and in vitro pharmacology of an antidote for dabigatran (aDabi-Fab). The X-ray crystal structure...

[Pharmacology of a new antidote unithiol].

Plenary Paper THROMBOSIS AND HEMOSTASIS A specific antidote for dabigatran: functional and structural characterization

Thromboembolic disorders such as myocardial infarction, stroke, and venous thromboembolism are the most common causes of mortality and morbidity in Western societies. These thromboembolic events can be triggered by excessive activation of coagulation, and thrombin plays a major role in these processes. The most widely used agents for antithrombotic therapy are indirect thrombin inhibitors (such...

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran

BACKGROUND AND PURPOSE Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world exp...

Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model

INTRODUCTION New oral anticoagulants are effective alternatives to warfarin. However, no specific reversal agents are available for life-threatening bleeding or emergency surgery. Using a porcine model of trauma, this study assessed the ability of prothrombin complex concentrate (PCC), activated PCC (aPCC), recombinant FVIIa (rFVIIa) and a specific antidote to dabigatran (aDabi-Fab) to reverse ...